AngioDynamics, Inc.

AngioDynamics, Inc. (ANGO) Stock Analysis

$12.170

-0.192 (-1.58%)At close

Loading chart…
High
12.390
Open
12.320
VWAP
12.24
Volume
458.83K
Mkt Cap
237.52M
Low
12.145
Amount
5.61M
EV/EBITDA, TTM
-95.26

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. The Med Tech segment is comprised of its technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment includes its Core, Venous, Ports and other Oncology products. Its product types are Ablation, Catheters, Medical Balloons, and Ports. The Catheter products include Angiographic Catheters, Uni-Fuse Infusion Catheter and Drainage Catheters.

AI analysis of AngioDynamics, Inc. (ANGO)

Buy

AngioDynamics Inc is a good buy right now due to its current price of $12.365, which is significantly below the analyst price targets of $19 to $20. The stock has shown a positive momentum with a 5-day change of +10.01%, and the RSI is at 57.536, suggesting it is neither overbought nor oversold. However, the main risk is the projected losses of $0.24 to $0.29 per share for fiscal 2027, indicating ongoing financial challenges.

Analyst Ratings (5)

+58.83% upside
Hold
1 Buy
4 Hold
0 Sell
Current: 12.17
Low
16.00
Average
19.33
High
24.00

Canaccord

2026-07-15

Price Target

$20

Buy

H.C. Wainwright

2026-07-15

Price Target

$19

Buy

Freedom Broker

2026-04-06

Price Target

$16

Buy

Canaccord

2026-04-06

Price Target

$16

Buy

Canaccord

2025-07-16

Price Target

$17

Buy

Valuation Metrics

The current forward P/E ratio for AngioDynamics, Inc. (ANGO) is 96.15, compared to its 5-year average forward P/E of -36.05.

Forward P/E

Fair
5Y Average P/E
-36.05
Current P/E
96.15
Overvalued
218.54
Undervalued
-290.64

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-162.95
Current EV/EBITDA
-95.26
Overvalued
482.07
Undervalued
-807.98

Forward P/S

Fair
5Y Average P/S
1.53
Current P/S
1.47
Overvalued
2.17
Undervalued
0.89

Alphio AI Price Scenarios for ANGO

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ANGO

$10.16

Scenario price

B

Base

Base · 50%ANGO

$9.75

Scenario price

B

Bear

Bear · 25%ANGO

$9.26

Scenario price

Whales holding ANGO

A

Armistice Capital LLC

+ HoldingANGO

-5.69%

3M Return

S

Systematic Financial Management LP

+ HoldingANGO

-6.98%

3M Return

Events Timeline

2026-10-21 (ET)

09:00:00

AngioDynamics Announces IRE Study Results, Patients' Survival Extended to 28 Months

2026-10-14 (ET)

07:30:00

AngioDynamics' NanoKnife System Covered by Humana's Updated Medicare Policy

2026-10-08 (ET)

16:30:00

Major Averages Decline Amid Rising Oil Prices

12:30:00

Major Averages Decline as Oil Prices Surge

09:00:00

Stock Futures Lower as Oil Prices and Treasury Yields Rise

News

ANGO FAQ — answered by Alphio AI

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. The Med Tech segment is comprised of its technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment includes its Core, Venous, Ports and other Oncology products. Its product types are Ablation, Catheters, Medical Balloons, and Ports. The Catheter products include Angiographic Catheters, Uni-Fuse Infusion Catheter and Drainage Catheters. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

AngioDynamics Inc is a good buy right now due to its current price of $12.365, which is significantly below the analyst price targets of $19 to $20. The stock has shown a positive momentum with a 5-day change of +10.01%, and the RSI is at 57.536, suggesting it is neither overbought nor oversold. However, the main risk is the projected losses of $0.24 to $0.29 per share for fiscal 2027, indicating ongoing financial challenges.

5 analysts cover ANGO: 1 rate it Buy, 4 Hold and 0 Sell. The average price target is 19.33.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading